Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Volcano888 who wrote (3492)	4/20/2001 5:15:47 PM
From: aknahow	Respond to of 52153

Online non financial part of XOMA annual report. Information on Xanelim the DNA psoriasis drug plus other efforts. Regardless of what one thinks of XOMA, if one thinks Genentech has a winner with Xanelim, then XOMA provides more leverage. Not sure more leverage is needed with biotechs but..... <g> xoma.com Xoma which is widely disliked by many knowledgeable posters on S.I. has acquired an institutional following, up from about 2% a year ago to over 37% of the outstanding shares. It has put in a strong technical performance recently. As one of the non knowledgeable S.I. posters I like XOMA and have a position. Bent over, is what some might call it. <g>

To: Volcano888 who wrote (3492)	4/20/2001 5:31:01 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Volcano, The FDA inner workings are not normally publicized. The advisory committee by contrast is public, and the transcripts of, e.g., the Aslera meeting will eventually be posted on the web. If you have never read an AC meeting transcript I urge you to do so - they are very educational indeed. (An interesting and still topical one was the original review of SCIOS's Natrecor). I don't know what the "straw poll" refers to - likely it was at the AC meeting. If so, and if it was on the record, the details will appear in the transcript. As you say, the final decision is made by the FDA, not the AC. Basically I believe it is the Office of Review Management at the CDER within the FDA that typically make the decision, although on controversial drugs it may go higher and involve the Commissioner. Some of the drug approval procedure is discussed at the FDA site. Take a look at: fda.gov Peter